bioRxivCancer BiologyPreprint
The Deacetylases HDAC1 and HDAC2 Safeguard BCR-ABL-positive Cells from Replication Stress-Induced Apoptosis via the Nuclear to Mitochondrial p73-NOXA Axis
Al‐Hassan M. MustafaiD, Miriam Pons, Nisintha Mahendrarajah, Maren Wiegerling, Jörg HartkampiD, Markus ChristmanniD, Markus Philipp RadsakiD, Günter SchneideriD, Matthias WirthiD, Oliver Holger KrämeriD
Abstract
Histone deacetylases (HDACs) are key epigenetic regulators that are frequently dysregulated in cancer cells. Context-specific dependencies of tumor cell survival on HDACs and the mechanisms through which HDACs determine cell stress responses by specific oncogenic pathways remain to be understood. Here we unravel how the class I deacetylases HDAC1 and HDAC2 control the fate of chronic myeloid leukemia (CML) cells undergoing DNA replication stress. Compared to normal myeloid cells (n=690), CML cells overexpress HDAC1 and HDAC2 (n=234-274). We reveal that HDAC1 and HDAC2 protect cultured and primary CML cells with the hyperactive BCR-ABL tyrosine kinase from programmed cell death through apoptosis upon DNA replication stress. Using transcriptomics and genetically defined knockdown and knockout model systems, we demonstrate that these effects depend on the transcription factor p73 and its pro-apoptotic target gene NOXA. Upon DNA replication stress, p73 binds to the NOXA promoter but only upon additional inactivation of HDAC1/HDAC2 the NOXA gene becomes transcribed. BCR-ABL translocate to the nucleus to catalyze p73 phosphorylation at tyrosine-99 for the induction of p73 and mitochondrial NOXA. Thus, the BCR-ABL oncogene creates a selective vulnerability to HDAC1/HDAC2 inhibitors, driving a cytotoxic shift in replication stress responses towards apoptosis. These data highlight HDAC1/HDAC2 as potential therapeutic targets in CML. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC="FIGDIR/small/694110v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@1ec0c51org.highwire.dtl.DTLVardef@1cd759org.highwire.dtl.DTLVardef@17e29a8org.highwire.dtl.DTLVardef@1e0fb50_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of HDAC7 reprograms the histone H3.3 landscape to induce heterochromatin spreading and DNA replication defects in cancer cells.
O. Hassan, M. Pizzagalli, … N. Tapinos·bioRxiv·Mar 12, 2024
- HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy
Maša Zrimšek, Kristina Draganić, … Gerda Egger·LeukemiaPeer-reviewed·Apr 2, 2025
- Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells
M. A. Fischer, A.-H. M. Mustafa, … O. H. Kramer·bioRxiv·Mar 9, 2023
- Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities
Y. Zhang, D. Remillard, … M. A. Erb·bioRxiv·May 30, 2022
- HDAC1 regulates the chromatin landscape to establish transcriptional dependencies in chronic lymphocytic leukemia
T.-h. Lai, H. G. Ozer, … D. Sampath·bioRxiv·Aug 3, 2020
- HDAC10 blockade upregulates SPARC expression thereby repressing melanoma cell growth and BRAF inhibitor resistance